Autoantibodies and scleroderma phenotype define subgroups at high-risk and low-risk for cancer

Article info

Clinical and epidemiological research

Takeru Igusa Departments of Civil Engineering and Applied Mathematics and Statistics, Johns Hopkins University, Baltimore, Maryland, USA PubMed articles Google scholar articles
Laura K Hummers Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA PubMed articles Google scholar articles
Kala Visvanathan Departments of Epidemiology and Medical Oncology, Johns Hopkins Bloomberg School of Public Health and Johns Hopkins University School of Medicine, Baltimore, Maryland, USA PubMed articles Google scholar articles
Carrie Richardson Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA PubMed articles Google scholar articles
Fredrick M Wigley Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA PubMed articles Google scholar articles
Livia Casciola-Rosen Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA PubMed articles Google scholar articles
Antony Rosen Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA PubMed articles Google scholar articles
Ami A Shah Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA PubMed articles Google scholar articles

Correspondence to Dr. Ami A Shah, Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD 21224, USA; Ami.Shah{at}jhmi.edu

Citation

Igusa T, Hummers LK, Visvanathan K, et al

Autoantibodies and scleroderma phenotype define subgroups at high-risk and low-risk for cancer

Annals of the Rheumatic Diseases 2018;77:1179-1186.

Online issue publication

October 18, 2019